Royalty Historical Income Statement

RPRX Stock

USD 26.60 0.31 1.18%

Historical analysis of Royalty Pharma income statement accounts such as Selling General Administrative of 262.2 M, Gross Profit of 1.4 B, Operating Income of 1.1 B or Net Income From Continuing Ops of 1.1 B can show how well Royalty Pharma Plc performed in making a profits. Evaluating Royalty Pharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Royalty Pharma's future profits or losses.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Royalty Pharma Plc latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Royalty Pharma Plc is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Royalty Pharma Plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

About Royalty Income Statement Analysis

Royalty Pharma Plc Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Royalty Pharma shareholders. The income statement also shows Royalty investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Royalty Pharma Income Statement Chart

At this time, Royalty Pharma's Interest Expense is fairly stable compared to the past year. Total Revenue is likely to rise to about 2.5 B in 2024, whereas Gross Profit is likely to drop slightly above 1.4 B in 2024.

Research Development Selling General Administrative Total Other Income Expense Net Other Operating Expenses Ebitda

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Royalty Pharma Plc. It is also known as Royalty Pharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Royalty Pharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Royalty Pharma Plc current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Royalty Pharma Plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	23.0M	5.7M	395.1M	414.9M
Interest Income	53.5M	78.3M	72.3M	45.0M

Depreciation And Amortization Interest Income

Royalty Pharma income statement Correlations

	Total Revenue	Research Development	Cost Of Revenue	Selling General Administrative	Operating Income	Net Income From Continuing Ops	Ebit	Income Before Tax	Total Other Income Expense Net	Net Income	Net Interest Income	Interest Income	Depreciation And Amortization	Other Operating Expenses	Ebitda	Reconciled Depreciation	Minority Interest	Non Operating Income Net Other	Non Recurring
Total Revenue		0.53	0.53	0.91	0.86	0.8	0.86	0.8	0.25	0.63	0.75	0.81	0.44	0.42	0.54	-0.75	-0.03	-0.66	-0.46
Research Development	0.53		0.04	0.24	0.46	0.42	0.46	0.42	0.32	0.44	0.14	0.37	-0.12	0.04	0.06	-0.08	0.15	-0.29	0.09
Cost Of Revenue	0.53	0.04		0.46	0.75	0.75	0.75	0.75	0.03	0.83	0.19	0.31	0.51	0.2	0.93	-0.51	-0.48	-0.17	-0.51
Selling General Administrative	0.91	0.24	0.46		0.66	0.58	0.66	0.58	0.12	0.36	0.92	0.89	0.63	0.6	0.42	-0.92	-0.17	-0.77	-0.64
Operating Income	0.86	0.46	0.75	0.66		0.96	1.0	0.96	0.09	0.87	0.43	0.56	0.22	0.22	0.83	-0.51	0.05	-0.37	-0.22
Net Income From Continuing Ops	0.8	0.42	0.75	0.58	0.96		0.97	1.0	0.29	0.92	0.31	0.41	0.28	0.0	0.84	-0.4	-0.01	-0.25	-0.25
Ebit	0.86	0.46	0.75	0.66	1.0	0.97		0.97	0.14	0.88	0.41	0.53	0.22	0.2	0.82	-0.49	0.06	-0.35	-0.22
Income Before Tax	0.8	0.42	0.75	0.58	0.96	1.0	0.97		0.29	0.92	0.31	0.41	0.28	0.0	0.84	-0.4	-0.01	-0.25	-0.25
Total Other Income Expense Net	0.25	0.32	0.03	0.12	0.09	0.29	0.14	0.29		0.33	-0.12	-0.09	0.28	-0.35	-0.09	0.0	-0.31	0.19	-0.24
Net Income	0.63	0.44	0.83	0.36	0.87	0.92	0.88	0.92	0.33		0.03	0.23	0.23	-0.03	0.82	-0.26	-0.21	-0.07	-0.2
Net Interest Income	0.75	0.14	0.19	0.92	0.43	0.31	0.41	0.31	-0.12	0.03		0.91	0.54	0.67	0.19	-0.87	-0.04	-0.88	-0.54
Interest Income	0.81	0.37	0.31	0.89	0.56	0.41	0.53	0.41	-0.09	0.23	0.91		0.48	0.75	0.27	-0.89	-0.15	-0.83	-0.44
Depreciation And Amortization	0.44	-0.12	0.51	0.63	0.22	0.28	0.22	0.28	0.28	0.23	0.54	0.48		0.22	0.37	-0.76	-0.78	-0.47	-0.95
Other Operating Expenses	0.42	0.04	0.2	0.6	0.22	0.0	0.2	0.0	-0.35	-0.03	0.67	0.75	0.22		0.02	-0.7	-0.16	-0.65	-0.25
Ebitda	0.54	0.06	0.93	0.42	0.83	0.84	0.82	0.84	-0.09	0.82	0.19	0.27	0.37	0.02		-0.39	-0.19	-0.15	-0.35
Reconciled Depreciation	-0.75	-0.08	-0.51	-0.92	-0.51	-0.4	-0.49	-0.4	0.0	-0.26	-0.87	-0.89	-0.76	-0.7	-0.39		0.44	0.72	0.75
Minority Interest	-0.03	0.15	-0.48	-0.17	0.05	-0.01	0.06	-0.01	-0.31	-0.21	-0.04	-0.15	-0.78	-0.16	-0.19	0.44		0.07	0.71
Non Operating Income Net Other	-0.66	-0.29	-0.17	-0.77	-0.37	-0.25	-0.35	-0.25	0.19	-0.07	-0.88	-0.83	-0.47	-0.65	-0.15	0.72	0.07		0.48
Non Recurring	-0.46	0.09	-0.51	-0.64	-0.22	-0.25	-0.22	-0.25	-0.24	-0.2	-0.54	-0.44	-0.95	-0.25	-0.35	0.75	0.71	0.48

Click cells to compare fundamentals

Royalty Pharma Account Relationship Matchups

Royalty Pharma income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	268.6M	157M	166.1M	188.0M	187.2M	196.5M
Total Revenue	1.8B	2.1B	2.3B	2.2B	2.4B	2.5B
Research Development	83.0M	26M	200.1M	177.1M	52M	57.5M
Cost Of Revenue	1.0B	88.1M	23.0M	5.7M	560.7M	588.7M
Selling General Administrative	103.4M	182M	182.8M	227.3M	249.7M	262.2M
Gross Profit	794.9M	2.0B	2.3B	2.2B	1.8B	1.4B
Operating Income	2.6B	1.6B	1.4B	977.5M	1.5B	1.1B
Net Income From Continuing Ops	2.5B	1.7B	1.2B	230.1M	1.7B	1.1B
Ebit	2.6B	1.7B	1.4B	922.9M	1.5B	1.2B
Total Operating Expenses	(808.9M)	527M	858.7M	1.3B	862.4M	905.5M
Income Before Tax	2.5B	1.7B	1.2B	230.1M	1.7B	1.1B
Total Other Income Expense Net	(161.8M)	106.6M	(189.5M)	(77.0M)	207.9M	218.3M
Net Income Applicable To Common Shares	2.3B	975.0M	619.7M	42.8M	49.3M	46.8M
Net Income	2.3B	495.2M	478.8M	42.8M	1.1B	771.0M
Income Tax Expense	349.3M	1.1B	762.4M	187.2M	565.3M	438.6M
Net Interest Income	(246.2M)	(157M)	(112.6M)	(109.6M)	(114.9M)	(120.6M)
Interest Income	22.3M	28.4M	53.5M	78.3M	72.3M	45.0M
Depreciation And Amortization	14.1M	23.1M	23.0M	5.7M	395.1M	414.9M
Other Operating Expenses	808.9M	527M	858.7M	1.3B	862.4M	858.0M
Ebitda	2.6B	1.7B	1.5B	928.6M	1.9B	1.8B
Minority Interest	35.9M	726.9M	621.5M	187.2M	(565.3M)	(537.0M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Royalty Stock Analysis

When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Royalty Historical Income Statement

About Royalty Income Statement Analysis

Royalty Pharma Income Statement Chart

Other Operating Expenses

Royalty Pharma income statement Correlations

Royalty Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Royalty Pharma income statement Accounts

Also Currently Popular

Additional Tools for Royalty Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebit	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Net Income From Continuing Ops
Ebit	+ 0.97	Net Income From Continuing Ops
Income Before Tax	+ 0.97	Ebit
Net Income From Continuing Ops	+ 0.96	Operating Income
Income Before Tax	+ 0.96	Operating Income

Non Recurring	- 0.95	Depreciation And Amortization
Reconciled Depreciation	- 0.92	Selling General Administrative
Reconciled Depreciation	- 0.89	Interest Income
Non Operating Income Net Other	- 0.88	Net Interest Income
Reconciled Depreciation	- 0.87	Net Interest Income
Non Operating Income Net Other	- 0.83	Interest Income